health_en

MagicTouch SCB receives IDE approval for In-Stent Restenosis indication

The US FDA has granted an Investigational Device Exemption (IDE) approval for MagicTouch Sirolimus Coated Balloon (SCB) indicated for In-Stent Restenosis (ISR). US FDA’s IDE approval allows the MagicTouch SCB to be used in a pivotal clinical study to support safety and effectiveness of this combination product. The data generated from this IDE clinical study will support a pre-market […]

thaipr.net

20 ก.ย. 65

First patient enrolled in Erectile Dysfunction prospective randomized study with SELUTION SLR

An 82-year-old Taiwanese man has become the first patient to be enrolled in the initial Erectile Dysfunction (ED) randomized clinical trial (RCT) involving SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon.   The PERFECT-SELUTION FIM (PElvic Revascularization For EreCTile dysfuction-SELUTION First-In-Man) study involves a total of 54 patients suffering from distal internal pudendal-penile artery stenotic disease and ED. They are…

thaipr.net

16 ก.ย. 65

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

Concept Medical announces the successful completion of the TRANSFORM 1 RCT (TReAtmeNt of Small coronary vessels: Randomized controlled trial FOR MagicTouch Sirolimus Coated Balloon). The Randomized Controlled Trial (RCT) was conceptualized with the aim of understanding how the treatment indications and applications of Drug Coated Balloon (DCB) in coronary artery disease (CAD) can be broadened. This prospective, randomized, multi-centre,…

thaipr.net

15 ก.ย. 65

Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence

Debiopharm Innovation Fund strategically invests in Whitelab Genomics’ mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm (www.Debiopharm.com), announced today their investment in Whitelab Genomics alongside French Venture Capital company, Omnes Capital, in […]

thaipr.net

14 ก.ย. 65

Turn Biotechnologies launches eTurna™ delivery platform designed specifically to enable nucleic acid therapeutics

The proprietary platform is versatile, equally effective with different cargoes, routes of administration Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced it has created a novel platform to safely and effectively deliver nucleic acid therapeutics – a major expansion of the company’s business. The eTurna Platform™ […]

thaipr.net

14 ก.ย. 65

DarwinHealth Publication Reports Step-by-Step Protocol for its Tumor Checkpoint-Based, Compound-to-Clinic (C2C) Cancer Drug Discovery Pipeline: Elucidates a Patient-to-Model-to-Patient (PMP) Roadmap for Precision- and Mechanism-Based Identification and Clinical Validation of Novel, Investigational and FDA-Approved Therapeutic Agents Targeting Tumor Regulatory Architecture

DarwinHealth, Inc., (www.DarwinHealth.com) a New York-based biotechnology and cancer drug discovery company announces the September 9, 2022 online publication in Current Protocols (Wiley Science) of their proprietary cancer drug discovery and validation pipeline, “A Patient-to-Model-to-Patient (PMP) cancer drug and biomarker discovery protocol for identifying and validating therapeutic agents targeting tumor regulatory architecture.”…

thaipr.net

13 ก.ย. 65
1 … 59 60 61 62 63 … 128

Copyright © 2025 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.